NK Cell Therapy Pipeline Analysis: 100+ Companies are Working to Improve the Treatment Space | DelveInsight

DelveInsight's, "NK Cell Therapy Pipeline Insight, 2022," report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in NK Cell Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from NK Cell Therapy Pipeline Report
• DelveInsight's NK Cell Therapy Pipeline report depicts a robust space with 100+ active players working to develop 185+ pipeline therapies for NK Cell Therapy treatment.
• The leading NK Cell Therapy Companies such as ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivax, Affimed, Celularity, Glycostem Therapeutics (IPD Therapeutic), SYNIMMUNE, Celyad, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Cytovia Therapeutics, CytoImmune Therapeutics, Exacis Biotherapeutics, Novocellbio, Kuur Therapeutics (Former name: Cell Medica), Fate Therapeutics, Feldan Therapeutics, iCell Gene Therapeutics, Innate Pharma, Nkarta Therapeutics, Surface Oncology, Kiadis Pharma, Vycellix, INmune Bio, CiMass, Glycostem, Five Prime Therapeutics, Multimmune GmbH, Ambicion, CARsgen therapeutics, Kuur Therapeutics, Celyad, Dragonfly Therapeutics, GamidaCell, NantKwest, Asclepius Technology Company, AffimedTherapeutics, Apceth Biopharma, Zelluna Immunotherapy, Catamaran Bio, ONK Therapeutics, Orgenesis, Navrogen, NKMAX, Nektar Therapeutics, Affimed Therapeutics, HerbiCell, Bristol-Myers Squibb, CellProtect Nordic Pharmaceuticals, CytoVac, Green Cross Corporation, NantKwest, PersonGen BioTherapeutics (Suzhou), GT Biopharma (formerly Oxis International Inc.), Nektar Therapeutics, Artiva Biotherapeutics, Senti Biosciences, oNKo-innate, Affimed Therapeutics, Agenus, Chongqing Sidemu Biotechnology, NKGen Biotech, Caribou Biosciences, Gamida-Cell, Wugen, Molmed, Century Therapeutics, KSQ Therapeutics, GT Biopharma, Shoreline Biosciences, Indapta Therapeutics, HebeCell, Sorrento therapeutics, Appia Bio, Cellatoz Therapeutics, Sanofi, Glycotype, CiMaas, CoImmune, Editas Medicine, Healios, Chimeric Therapeutics, Rubius Therapeutics, Oncternal Therapeutics, MedXCell, MiNK Therapeutics, Phio Pharmaceuticals, Biohaven Pharmaceuticals, Lava therapeutics, Allogene Therapeutics/Notch Therapeutics, Onward therapeutics, Miltenyi Biotec, and others are developing novel drug candidates to improve the NK Cell Therapy treatment landscape.
• The promising NK Cell Therapies in the various stages of development stages includes FATE-NK100, Cetuximab, Trastuzumab, FT500, Brentuximab Vedotin, Cytarabine, and others.
• The companies and academics are working to assess challenges and seek opportunities that could influence Natural Killer (NK) cell therapy R&D. The therapies under development are focused on novel approaches to treat/improve Natural Killer (NK) cell therapy.

Get an overview of the NK Cell Therapies Pipeline landscape @ https://www.delveinsight.com/report-store/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

NK Cell Therapies Overview
Natural killer cells, also known as NK cells are a type of lymphocytes and are key components of the innate immune system. They are highly specific predators that play a major role in the host rejection of both tumors and viral infected cells. NK cells have cytotoxic small granules, which contain special proteins such as perforins and proteases, are known as granzymes in their cytoplasm. Perforins form pores in the cell membrane of the target cell through which the granzymes and associated molecules induce apoptosis. NK cells are derived from the common lymphoid progenitor cells (lymphoblasts), which also generate B and T lymphocytes. They differentiate and mature in the bone marrow, lymph nodes, spleen, tonsils, and thymus, where they then enter into the bloodstream. NK cell therapy has been most successful in hematopoietic malignancies, such as leukemias. NK cell immunotherapy can be achieved by either activating endogenous NK cell response by administering NK stimulants or using exogenous NK cells via HSCT or adoptive cell transfer. Several strategies for NK cell immunotherapies for human cancer have been proposed to date. The upcoming technologies and recent advances in understanding the manipulation of NK cell activation and development have led to the hope that NK cells could be harnessed as immunotherapy for cancers and other diseases.

Latest Breakthroughs in the NK Cell Therapy Treatment Landscape
• In February 2021, Nektar has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside the United States and Canada) for a Phase II/III study of Bempegaldesleukin.
• In December 2017, Five Prime and Zai Lab announced a strategic collaboration for the development and commercialization of bemarituzumab in Greater China.
• CytoSen's lead NK-cell therapy candidate, CSDT002-NK is now known as K-NK002 after the company being acquired by Kiadis Pharma in 2019
NK Cell Therapy Emerging Drugs
• NKTR-214: Nektar therapeutics
• Monalizumab: Innate Pharma
• Bemarituzumab: Five Prime Therapeutics
• ALT 803: ImmunityBio
• CellProtect: XNK Therapeutics
• K-NK002: Kiadis Pharma
• NK-92: ImmunityBio
• WU-NK-101: Wugen
• Anti-CD33 CAR-NK cells: PersonGen BioTherapeutics
• ALECSAT: CytoVac

Discover more about the therapy set to grab substantial NK Cell Therapy treatment landscape @ https://www.delveinsight.com/report-store/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

NK Cell Therapy Pipeline Therapeutics Analysis
There are approx. 100+ key companies which are developing the therapies for Natural Killer (NK) cell therapy. The companies which have their Natural Killer (NK) cell therapy drug candidates in the most advanced stage, i.e. Phase III include, Nektar therapeutics.

DelveInsight's NK Cell Therapy Pipeline Report covers around 185+ products under different phases of clinical development like-
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Discover more about therapy set to grab substantial NK Cell Therapy Pipeline landscape @ https://www.delveinsight.com/report-store/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the NK Cell Therapy Pipeline Report
• Coverage- Global
• NK Cell Therapy Companies- ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivax, Affimed, Celularity, Glycostem Therapeutics (IPD Therapeutic), SYNIMMUNE, Celyad, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Cytovia Therapeutics, CytoImmune Therapeutics, Exacis Biotherapeutics, Novocellbio, Kuur Therapeutics (Former name: Cell Medica), Fate Therapeutics, Feldan Therapeutics, iCell Gene Therapeutics, Innate Pharma, Nkarta Therapeutics, Surface Oncology, Kiadis Pharma, Vycellix, INmune Bio, CiMass, Glycostem, Five Prime Therapeutics, Multimmune GmbH, Ambicion, and others
• NK Cell Therapy Drugs- FATE-NK100, Cetuximab, Trastuzumab, FT500, Brentuximab Vedotin, Cytarabine, and others
• NK Cell Therapy Pipeline Assessment by Product Type
• NK Cell Therapy Pipeline Assessment by Stage and Product Type
• NK Cell Therapy Pipeline Assessment by Route of Administration
• NK Cell Therapy Pipeline Assessment by Stage and Route of Administration
• NK Cell Therapy Pipeline Assessment by Molecule Type
• NK Cell Therapy Pipeline Assessment by Stage and Molecule Type

Table of Content
1. Introduction
2. Executive Summary
3. Natural Killer (NK) cell therapy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. NKTR-214: Nektar therapeutics
8. Mid Stage Products (Phase II)
9. CellProtect: XNK Therapeutics
10. Early stage products (Phase I/II)
11. Anti-CD33 CAR-NK cells: PersonGen BioTherapeutics
12. Inactive Products
13. Natural Killer (NK) cell therapy Key Companies
14. Natural Killer (NK) cell therapy Key Products
15. Natural Killer (NK) cell therapy- Unmet Needs
16. Natural Killer (NK) cell therapy- Market Drivers and Barriers
17. Natural Killer (NK) cell therapy- Future Perspectives and Conclusion
18. Natural Killer (NK) cell therapy Analyst Views
19. Natural Killer (NK) cell therapy Key Companies
20. Appendix

Got Queries? Reach out for more information on the NK Cell Therapy Pipeline Report @ https://www.delveinsight.com/report-store/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09193216187
Address: 304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.